1. Home
  2. OLP vs DSGN Comparison

OLP vs DSGN Comparison

Compare OLP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo One Liberty Properties Inc.

OLP

One Liberty Properties Inc.

HOLD

Current Price

$22.70

Market Cap

508.4M

Sector

Real Estate

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$10.28

Market Cap

579.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLP
DSGN
Founded
1982
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
508.4M
579.9M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
OLP
DSGN
Price
$22.70
$10.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$27.50
$15.25
AVG Volume (30 Days)
61.8K
242.4K
Earning Date
03-05-2026
03-09-2026
Dividend Yield
7.94%
N/A
EPS Growth
N/A
N/A
EPS
1.15
N/A
Revenue
$82,740,000.00
N/A
Revenue This Year
$7.76
N/A
Revenue Next Year
$4.51
N/A
P/E Ratio
$19.73
N/A
Revenue Growth
1.02
N/A
52 Week Low
$19.62
$2.62
52 Week High
$26.86
$11.23

Technical Indicators

Market Signals
Indicator
OLP
DSGN
Relative Strength Index (RSI) 46.99 50.78
Support Level $21.94 $9.64
Resistance Level $23.63 $11.14
Average True Range (ATR) 0.62 0.59
MACD -0.15 0.03
Stochastic Oscillator 28.78 42.21

Price Performance

Historical Comparison
OLP
DSGN

About OLP One Liberty Properties Inc.

One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: